Expecting a Big Move in Isis Pharma

I have posted previously (several times, in fact) re the growing opportunity for us investors in Isis Pharmaceuticals (ISIS). Remember, this company has a key statin deep into the clinical trials process, and all accounts have it that this drug shows a marked improvement over other statins currently available or in the pipeline. (Including the one from Arena Pharmaceuticals (ARNA).) This helps make the company a leading takeover candidate by an old-line ethical drug manufacturer such as Pfizer (PFE), whose own drug felled its hopes to create one internally. I prefer a buyout does not occur... Well, at least not yet.

So, yes, a big move appears imminent, as ISIS shares near an inflection point; in fact, two inflection points. Multiple levels of support lie at ~$10.75, ~50¢ below yesterday's last trade. Multiple levels of resistance converge at ~$11.50, ~30¢ above yesterday's close. This translates as an approximately 9% range between the two. This squeeze can continue to compress, could even breakdown albeit ephemerally, but upside momentum is busily and quickly refreshing itself. The moment -- an upside breakout -- seems nigh.

Thus, I place this opportunity front & center. It joins other recent winners, which includes among other favorites, Apple Computer (AAPL) (remember that one, naysayers?) and Zumiez (ZUMZ) -- which also nears an explosive move higher.

ISIS 1-yr chart:

Comments

[Jon JonMacky]

I am glad you are postive on ISIS, but I think you should check your facts. 301012 isn't a statin at all. In fact, that's one of the big reasons it's so attracive in the first place. The results are as good or better than with statins, but has not shown any of their nasty side effects.

Please don't be like Cramer. He once said on this show "I like Isis, I think they are going to beat that Crohn's disease." Too bad that drug had failed 6 months earlier....

[David MGordon]

Thank you for your comments, Jon Jon.

The mention of "301012" in fact is made by <b>The Medical Technology Stock Letter</b>, not me. I added his thoughts in the comments area of my blog for added depth of understanding.

It seems <i>you</i> know this stuff very well indeed; My regular readers would appreciate it were you to add your comments -- and any other remarks -- as a reply on my blog. Certainly, I would!

Best wishes,
David